TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06351150: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Trial to Evaluate the Efficacy and Safety of Angiotensin II Injection in the Background Treatment of Catecholamines and Other Vasopressors in Chinese

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 214 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$9,098,792

Rescue Site Savings

+$5,987,288

Unlock Full NCT06351150 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06351150 Rescue Dossier →